文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

80岁及以上中危前列腺癌患者剂量递增放疗联合或不联合雄激素剥夺治疗的总生存分析

Overall Survival in Men 80 and Older With Intermediate-Risk Prostate Cancer Who are Treated With Dose-Escalated Radiation and Androgen Deprivation Therapy Versus Dose-Escalated Radiation Alone: A National Cancer Database Analysis.
PubMed 文献 · Adv Radiat Oncol · 2025-12-11

该研究基于美国国家癌症数据库(NCDB)回顾性分析≥60岁中危前列腺癌患者接受剂量递增放疗(EQD2α/β=2 ≥74 Gy)联合或不联合雄激素剥夺治疗(ADT)的总生存。

要点

  • 60-69岁中危前列腺癌患者,剂量递增放疗联合ADT可改善总生存。

核心结论

  • 在60-69岁中危前列腺癌患者中,剂量递增放疗联合ADT与总生存改善相关。
  • 在80岁及以上患者中,剂量递增放疗联合ADT未显示总生存获益。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库(NCDB)。
  • 纳入≥60岁接受剂量递增放疗(EQD2α/β=2 ≥74 Gy)的中危前列腺癌患者。
  • 中危定义:PSA >10且≤20,或Gleason评分7(3+4或4+3),或T2期。
  • 按年龄(60-69、70-79、≥80岁)和是否接受ADT分组,采用Kaplan-Meier和Cox比例风险模型分析总生存。

主要发现

  • 共纳入10,168例接受RT+ADT和12,396例接受单纯RT的患者。
  • ≥80岁患者中,672例(6.6%)接受ADT,772例(6.2%)未接受ADT。

关键数值与推荐

  • 剂量递增放疗定义为EQD2α/β=2 ≥74 Gy。
  • 中危标准:PSA >10且≤20,或Gleason评分7(3+4或4+3),或T2期。

临床怎么用

  • 对于60-69岁中危前列腺癌患者,剂量递增放疗联合ADT可考虑作为改善总生存的策略。
  • 对于80岁及以上中危前列腺癌患者,联合ADT未显示总生存获益,决策时应个体化权衡。

局限性

  • 回顾性数据库分析,存在选择偏倚和未测量混杂因素。
  • ADT使用非随机分配,组间基线特征存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Men 80 and over are not well represented on randomized clinical trials, including the studies that examined the addition of androgen deprivation (ADT) to radiation therapy (RT). However, octogenarians may be a group particularly susceptible to the side effects of ADT due to the rapid increase in age-related changes as one enters their 9th decade. We hypothesized that ADT, when added to RT in octogenarians with intermediate-risk prostate cancer, might be associated with worse overall survival, and that this effect would not hold for their younger counterparts. METHODS AND MATERIALS: The National Cancer Database (NCDB) was queried for men ≥60 years old who received dose-escalated RT (EQD2α/β=2 ≥ 74 Gy) for intermediate-risk prostate cancer. Intermediate risk was defined as prostate specific antigen (PSA) > 10 and ≤ 20, Gleason score 7 (either 3+4 or 4+3), or T2 disease. Men were separated by age (60-69, 70-79, ≥80) and receipt of ADT. Overall survival was evaluated using Kaplan-Meier analysis. Cox proportional hazards were used to determine the relationship between ADT usage on survival in different age cohorts. RESULTS: There were 10,168 men who received RT + ADT versus 12,396 who received RT alone. In the RT + ADT group, a larger percentage of men had Gleason 4+3 disease (43% vs 26%, P = .004), T2 stage (35% vs 25%, P = .019), and a higher PSA (median 7.6 vs 6.8, P < .0001). There were 672 (6.6%) octogenarians who received ADT versus 772 (6.2%) who did not. Hazard ratios (HRs) for overall survival, accounting for Gleason score, T stage, PSA, and comorbid conditions, showed improved survival in those 60 to 69 with the addition of ADT to dose-escalated RT (HR = 0.90 [95% CI, 0.81-0.99], P = .039), while no difference in those 70-79 (HR = 0.98 [0.90-1.06], P = .541) or 80 and older (HR = 1.13 [0.97-1.32], P = .124). CONCLUSIONS: In this NCDB analysis, the addition of ADT to dose-escalated radiation in men between the ages of 60 and 70 with intermediate-risk prostate cancer showed improved overall survival. However, adding ADT to dose escalation in those 80 and older did not demonstrate an overall survival benefit.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dougherty TP, Deng M, Hayes S, et al. Overall Survival in Men 80 and Older With Intermediate-Risk Prostate Cancer Who are Treated With Dose-Escalated Radiation and Androgen Deprivation Therapy Versus Dose-Escalated Radiation Alone: A National Cancer Database Analysis. Adv Radiat Oncol. 2025. PMID: 41568317. doi:10.1016/j.adro.2025.101977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。